Company News-Bio-Thera Solutions, Ltd.

Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

2026-05-18

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...

查看详情

10-092024

Bio-Thera and Richter Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, for EU countries, UK, Switzerland and other selected countries

Guangzhou, China/Budapest, Hungary– # October 9,2024 – Bio-Thera Solutions (688177:SH; “Bio-Thera”), a commercial-stageb...
09-112024

Bio-Thera Solutions and Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCETM (BAT1806/BIIB800), an approved Biosimilar referencing tocilizumab in Arthritis Research & Therapy

Comparable clinical efficacy and safety in Treatment Period 2 (TP2, Week 24-48) is maintained after switch from referenc...
08-162024

Bio-Thera Solutions and Pharmapark Further Expand Partnership in Russia and other CIS Countries with Addition of BAT2306, a Cosentyx® Biosimilar

GUANGZHOU, China and MOSCOW, Russia --- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stagebiopharmaceutical compan...

上一页 ···8 9 10 11 12 ··· 下一页